Core Viewpoint - The article highlights the successful IPO of Hangzhou Deshi Biotechnology Co., Ltd., marking it as the first stock in the Hong Kong market focused on medical imaging large models, with a market capitalization of approximately HKD 19.5 billion (around RMB 17.2 billion) at opening [3][4]. Company Overview - Deshi Biotechnology operates in the niche field of chromosome karyotype analysis, utilizing AI to provide intelligent analysis solutions for medical devices [4][20]. - The company has developed AI AutoVision® software and MetaSight® scanning system, automating the entire process from image scanning to result interpretation, significantly improving efficiency [4][24]. - In the first three quarters of 2025, the company reported revenue of RMB 112 million, a 470% year-on-year increase, with a gross margin of 75.9% [4][32]. Market Position - According to a report by Frost & Sullivan, Deshi Biotechnology holds a 30.6% market share in China for chromosome karyotype analysis, ranking first, whereas previously, over 95% of the market was dominated by German companies Zeiss and Leica [4][36]. - The market for chromosome karyotype analysis in China is projected to grow from RMB 120 million in 2019 to RMB 166 million by 2024, indicating a stable growth trajectory [36]. Founder Background - The founder, Song Ning, has a diverse academic background in computer science and medical genetics, which has influenced the company's innovative approach to integrating AI in medical diagnostics [8][9][10]. - Song Ning's vision was driven by the need for advanced genetic testing solutions in China, where a significant portion of couples face reproductive challenges due to genetic diseases [10][11]. Product Development - Deshi Biotechnology's AI AutoVision significantly reduces the analysis time for samples from approximately 34.1 minutes to about 11.3 minutes, allowing a single doctor to process around 50 samples daily [24][22]. - The company has developed a comprehensive product matrix that includes software, hardware, reagents, and consumables, addressing the entire workflow of chromosome karyotype analysis [22][21]. Financial Performance - The company has not yet achieved profitability but has shown a trend of narrowing losses, with net losses of RMB 56.1 million in 2023, RMB 43.4 million in 2024, and RMB 36.6 million in the first nine months of 2025 [34][32]. - As of September 30, 2025, the company had cash and cash equivalents of RMB 396 million, indicating a strong cash flow position [34]. Investment and Shareholding - Major shareholders include Hangzhou Zijin Port (9.88%), Shanghai Meihong (7.48%), and several other institutional investors, reflecting a diverse investment base [5][18]. - The article notes that some investors have seen returns as high as 90 times their initial investment following the company's IPO [15][19]. Industry Trends - The article discusses the shift in the chromosome karyotype analysis market from reliance on imported technologies to domestic innovations, with Deshi Biotechnology leading this change [36][39]. - The broader AI medical imaging market in China is expected to grow from RMB 1.1 billion in 2019 to RMB 138.2 billion by 2030, highlighting the increasing demand for automated solutions in medical diagnostics [40][42].